Epigenic Therapeutics to Present Company's Leading Drug Discovery Program Using Epigenetic Modulation Technology at ESGCT 2023

Epigenic Therapeutics, a leading biotechnology company dedicated to developing next-generation gene modulation therapy utilizing epigenome regulation to treat prevalent diseases, today announced to present a poster at European Society of Gene & Cell Therapy（ESGCT）Conference on October 24-27 at Brussels, Belgium. The poster is entitled “Profound and durable silencing of PCSK9 in non-human primates (NHPs) by Epigenome Modulation” (Poster ID: 679).

EPIREGTM, Epigenic’s core technology, offers a compelling alternative to the traditional cleavage-dependent gene editing tools which raise safety concerns due to altering the DNA sequence. By precisely modulating gene expression(s) at epigenetic levels, EPIREGTM is expected to achieve potent and durable silencing of target gene(s) to provide revolutionary and novel solutions to patients with chronic diseases.

The poster shows that with a single dose of administration of EPI-001 deep and sustainable repression of PCSK9 gene and protein expressions were achieved in multiple species, including mice and NHPs and humanized PCSK9 mice. It is demonstrated that EPIREGTM could be a potential novel class of anti-hypercholesterolemic therapeutics for treatment of patients with ASCVD.

About Epigenic Therapeutics

Epigenic Therapeutics is a frontier biotechnology company dedicated to developing next generation gene modulation therapy utilizing regulation of epigenetic genome for a variety of diseases. Founded in 2021 by leading scientists focused on discovering epigenetic engineering technologies and developing epigenetic therapies, the company has multiple projects in the pipeline, including treatment for metabolic, cardiovascular, viral hepatitis, ocular and rare diseases. For more information, please visit www.epigenictx.com

Contact

Partnering@epigenictx.com

Media@epigenictx.com

Investors@epigenictx.com